Vimarsana
Biggest News Aggregation in the World

Novel Third Generation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Novel Third Generation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Novel Third Generation Today - Breaking & Trending Today

China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List - Vimarsana News

China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

Published: January 19, 2023

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com
Related Topics:
United StatesHong KongWestern AustraliaInnovent BiologicsAscentage PharmaGujralt OlverembatinibEli LillyPrnewswire Ascentage PharmaDajun YangAdimab IncyteMichael YuXue Za ZhiMajor NationalMd Anderson Cancer CenterAmerican Society Of HematologyNational Major New Drug DiscoveryChina National Medical Products AdministrationEuropean UnionNational Healthcare Security AdministrationDana Farber Cancer InstituteNational Comprehensive Cancer NetworkDrug AdministrationNational Reimbursement Drug ListEuropean Medicines AgencyManufacturing Program
Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings - Vimarsana News

Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

Published: November 28, 2022

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Source: prnewswire.com
Related Topics:
United StatesHong KongQian JiangYing ChengInnovent BiologicsEli LillySelpercatinib Eli LillyAdimab IncyteZhijian XiaoCaicun ZhouUnion Medical CollegeSchool Of MedicineInstitute Of Hematology Blood Diseases HospitalPrnewswire Innovent Biologics IncMd Anderson Cancer CenterUniversity Institute Of HematologyUniversity People HospitalFirst Affiliated Hospital Of Suzhou UniversityZhejiang UniversityChinese Academy Of Medical SciencesIncyte CorporationProfessor Caicun ZhouShanghai Pulmonary HospitalFirst Affiliated HospitalCombination With Sintilimab
ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting - Vimarsana News

ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting

Published: November 3, 2022

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com
Related Topics:
United StatesHong KongAscentage PharmaDajun YangYifan ZhaiMajor NationalTanner Pharma GroupMd Anderson Cancer CenterAmerican Society Of HematologyNational Major New Drug DiscoveryChina National Medical Products AdministrationDana Farber Cancer InstituteChina Ministry Of ScienceCancer AssociationDrug AdministrationGlobal Named Patient ProgramEuropean Medicines AgencyPatient ProgramAmerican SocietyNew OrleansMajor New Drug ProjectChinese SocietyClinical OncologyChina Anti Cancer AssociationHolistic Integrative Management
ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting - Vimarsana News

ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting

Published: November 3, 2022

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com
Related Topics:
United StatesHong KongAscentage PharmaDajun YangYifan ZhaiMajor NationalTanner Pharma GroupMd Anderson Cancer CenterAmerican Society Of HematologyNational Major New Drug DiscoveryChina National Medical Products AdministrationDana Farber Cancer InstituteChina Ministry Of ScienceCancer AssociationDrug AdministrationGlobal Named Patient ProgramEuropean Medicines AgencyPatient ProgramAmerican SocietyNew OrleansMajor New Drug ProjectChinese SocietyClinical OncologyChina Anti Cancer AssociationHolistic Integrative Management
ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety - Vimarsana News

ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety

Published: December 14, 2021

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com
Related Topics:
United StatesHong KongQian JiangAscentage PharmaYifan ZhaiPrnewswire Ascentage PharmaXiaojun HuangMajor NationalMd Anderson Cancer CenterAmerican Society Of HematologyChina National Medical Products AdministrationHematology Department Of Peking University People HospitalNational Major New Drug DiscoveryDana Farber Cancer InstituteAmerican SocietyHematology DepartmentPeking University PeopleChief Medical OfficerEfficacy ResultsNovel Third GenerationKinase InhibitorResistant Chronic Myeloid LeukemiaOral PresentationMyeloid LeukemiaPivotal Phase